SEC Form 4 · accession 0001818524-26-000004
NEUROCRINE BIOSCIENCES INC · NBIX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Sanjay Chandru Keswani
Officer — Chief Medical Officer
Period of report
Jun 2, 2026
Accepted (ET)
Jun 4, 2026 · 5:54 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0000914475
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jun 2, 2026 | M | 3,212 | $0.00 | A | 3,212 | D | |
| Common StockF1 | Jun 2, 2026 | F | 1,733 | $154.84 | D | 1,479 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitF2,F3 | — | Jun 2, 2026 | M | 3,212 | D | — | — | Common Stock | 3,212 | 9,634 | D |
Explanation of responses
- F1Shares withheld by Neurocrine Biosciences, Inc. (the "Company" or "Issuer") to satisfy tax withholding requirements on vesting of restricted stock units ("RSUs"). No shares were sold.
- F2Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.
- F3This RSU was granted to the Reporting Person on June 2, 2025. In accordance with the terms of the RSU, the award vested as to 3,212 shares on June 2, 2026, and will vest as to 3,212 shares on June 2, 2027, 3,211 shares on June 2, 2028, and 3,211 shares on June 2, 2029, subject to the terms and conditions of the award.